FDA Grants Full Approval of Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
The FDA approved Deciphera Pharmaceuticals’ Quinlock (ripretinib) for the treatment of advanced gastrointestinal stromal tumors.
